GLY510 is designed to address the clinical needs not satisfied by current products. The product is in lead optimisation and will be developed for IV and subcutaneous administration.
There are significant opportunities to improve this treatment and the need for a product in such a key treatment focus area for major pharmaceutical companies, e.g. diabetes and cancer, makes this market highly attractive for GlycoForm's business model. The company will seek an early out-license partner.